Eli Lilly, an American pharmaceutical company, plans to disclose the results of a Phase 3 clinical trial for its obesity medication, Zepbound, which is also being developed as an oral drug, in the ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Cell therapy developers, especially early-stage companies, often face significant challenges scaling their manufacturing processes, requiring extensive investment in developing their own methods ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying ... Zepbound as a treatment for ...

Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people with relapsing and progressive forms of multiple sclerosis (MS).

That’s despite what the BMO analyst called “struggles” with the Alzheimer’s market, including barriers to reimbursement and the need to educate providers about appropriate treatment ... In a statement ...

our previous guidance had anticipated even faster acceleration of growth for the quarter,” Lilly CEO David Ricks said in a statement. In a presentation later in the day at JPM, Ricks explained ...

CEO David Ricks said the company expects to produce 60% more doses of the drugs in the first half of 2025 compared to last year. Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered ...

Indeed, the drug maker estimated that its Mounjaro weight loss treatment had generated revenue ... versus the mean estimate of $2.08 billion. CEO David Ricks reported that the U.S. weight-loss ...

Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

citing Eli Lilly's CEO David Ricks. Ricks said at the JPMorgan Healthcare Conference that the government needs to "fix" the Inflation Reduction Act (IRA) before the second round of talks over ...